Company Overview and News
2018-09-19 investorplace - 7
Now that the biotechnology sector is well on its way to bouncing back after bottoming in May 2018, investors may feel like they missed out. The fears that previously plagued biotech stocks are no longer as big a threat. The government is no longer putting companies hiking drug price in their cross-hairs, at least not for now. This favorable environment should help biotech firms carry out their plans for the rest of the year.
NKTR OPK EXEL CELGZ GERN JNJ CELG FOLD ALNY
2018-09-13 zacks - 2
Investors in Geron Corporation (GERN - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Sep 21, 2018 $2.50 Put had some of the highest implied volatility of all equity options today.
2018-09-12 globenewswire - 4
BERKELEY HEIGHTS, N.J., Sept. 12, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer biology, announced the appointment of Robert Spiegel, M.D., FACP, to its Board of Directors.
CYCCP CYCC GERN EDGE
2018-09-10 seekingalpha - 4
Thanks for joining us today! Welcome to Dr Zach Hartman and Amit Ghate, two well-known analysts on SeekingAlpha, and very luckily for us here at the Total Pharma Tracker, our two outstanding collaborators.
VTL MNKD TSRO EXEL NVCR GERN XNET TLRY BGNE AERI WATT RDUS
2018-09-04 zacks - 2
Geron Corporation (GERN - Free Report) shares have risen 218.3% so far this year against the industry’s decline of 1.7% as it makes rapid progress on the development of its sole pipeline candidate, imetelstat.
XLRN CELGZ GERN JNJ CELG
2018-08-28 seekingalpha - 4
Geron (GERN) is a sprightly thirty year old biotech that is awaiting big news. Johnson & Johnson's (JNJ) subsidiary Janssen is giving its imetelstat pipedot (Geron's pipeline has but this single therapy) a thorough review preparatory to making a key continuation decision under its 2014 collaboration agreement with Geron.
2018-08-25 investorplace - 4
Geron Corporation (NASDAQ:GERN) shares went gangbusters on Friday as one of its partners — Johnson & Johnson (NYSE:JNJ) — announced a job position that is linked with the pricing of a drug that the two companies have been developing and marketing together.
2018-08-24 seekingalpha - 12
Geron (GERN) presents a simple value proposition. If its contribution to cancer treatment can reel in the big fish that has been on its hook since 2014, Geron's investors will prosper. Otherwise not, or so the conventional thinking has been.
2018-08-20 investorplace - 2
From an overall perspective, biotech stocks have enjoyed respectable gains this year. The sector exchange-traded fund SPDR S&P Biotech ETF (NYSEARCA:XBI) is up double digits since January’s opening session. That said, the market movement has been anything but steady, with several key players suffering disappointing performances.
JAZZ EXEL GILD GERN JNJ CELG KMDA ABBV ALNY
2017-10-16 - Asif
Geron Corporation is a biopharmaceutical company that currently supports the clinical stage development of a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies, by Janssen Biotech, Inc., or Janssen. Early clinical data, including molecular responses in essential thrombocythemia, or ET, and remission responses, including reversal of bone marrow fibrosis, in myelofibrosis, or MF, suggest imetelstat may have disease-modifying activity by inhibiting the progenitor cells of the malignant clones for the underlying diseases. In November 2014, Geron entered into a collaboration and license agreement, or the Collaboration Agreement, pursuant to which the company granted Janssen the exclusive rights to develop and commercialize imetelstat worldwide for all indications in oncology, including hematologic myeloid malignancies, and all other human therapeutic uses. The Collaboration Agreement became effective in December 2014 and the company received $35 million from Janssen ...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Silicon Investor Message Boards
This table lists all message boards related to GERN / Geron Corp. on message board site Silicon Investor.
as of ET